175 related articles for article (PubMed ID: 3554371)
21. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
22. Effects of smoking on platelets and on plasma thromboxane-prostacyclin balance in man.
Mehta P; Mehta J
Prostaglandins Leukot Med; 1982 Aug; 9(2):141-50. PubMed ID: 6181530
[TBL] [Abstract][Full Text] [Related]
23. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
24. [The modification of the biosynthesis and effect of thromboxane A2 and prostacyclin by trapidil (Rocornal)].
Block HU; Heinroth I; Giessler C; Pönicke K; Mentz P; Zehl U; Rettkowski W; Dunemann A; Förster W
Biomed Biochim Acta; 1983; 42(2-3):283-99. PubMed ID: 6411078
[TBL] [Abstract][Full Text] [Related]
25. New trends in thromboxane and prostacyclin modulators.
Dogné JM; de Leval X; Delarge J; David JL; Masereel B
Curr Med Chem; 2000 Jun; 7(6):609-28. PubMed ID: 10702629
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs.
Tanabe M; Terashita Z; Nishikawa K; Hirata M
J Cardiovasc Pharmacol; 1984; 6(3):442-8. PubMed ID: 6202970
[TBL] [Abstract][Full Text] [Related]
27. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
28. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
30. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of platelet thromboxane generation by suloctidil in man.
Bucchi F; Cerletti C; de Gaetano G
Haemostasis; 1986; 16(5):362-8. PubMed ID: 3023210
[TBL] [Abstract][Full Text] [Related]
32. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart.
Sakai K; Ito K; Ogawa K
J Cardiovasc Pharmacol; 1982; 4(1):129-35. PubMed ID: 6176788
[TBL] [Abstract][Full Text] [Related]
33. Lack of association between Doppler velocimetry and synthesis of prostacyclin and thromboxane in umbilical cord vessels from growth retarded fetuses.
Saldeen P; Olofsson P; Marsál K
Acta Obstet Gynecol Scand; 1995 Feb; 74(2):103-8. PubMed ID: 7900504
[TBL] [Abstract][Full Text] [Related]
34. Thromboxane A2 and prostacyclin release in bleeding time blood during primary haemostasis in healthy individuals.
Thorngren M; Vinge E
Acta Med Scand; 1988; 223(2):187-90. PubMed ID: 3279726
[TBL] [Abstract][Full Text] [Related]
35. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
36. The effect of oral contraceptives on antiaggregatory prostacyclin and proaggregatory thromboxane A2 in humans.
Ylikorkala O; Puolakka J; Viinikka L
Am J Obstet Gynecol; 1982 Mar; 142(5):573-6. PubMed ID: 7036746
[TBL] [Abstract][Full Text] [Related]
37. Maternal prostacyclin, thromboxane, and placental blood flow.
Ylikorkala O; Jouppila P; Kirkinen P; Viinikka L
Am J Obstet Gynecol; 1983 Mar; 145(6):730-2. PubMed ID: 6338724
[TBL] [Abstract][Full Text] [Related]
38. Modulation of vascular thrombosis by products of arachidonic acid metabolism.
Wu KK; Hall ER; Papp A
Clin Physiol Biochem; 1984; 2(2-3):84-90. PubMed ID: 6435930
[TBL] [Abstract][Full Text] [Related]
39. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
[TBL] [Abstract][Full Text] [Related]
40. [Effect of bilateral common carotid artery ligation on prostaglandin levels (TXA2, PGI2) in spontaneously hypertensive rats (SHRSP, SHRSR) and normotensive rats (WKY)].
Katayama Y; Suzuki S; Shimizu J; Inamura K; Sugimoto S; Terashi A
No To Shinkei; 1986 Jun; 38(6):571-8. PubMed ID: 3524627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
